MarkRubens / iStockphoto.com
26 June 2018Asia-Pacific
Australia’s competition regulator seeks to appeal Pfizer judgment
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Asia-Pacific
31 May 2018 A court has rejected an appeal by the Australian Competition and Consumer Commission, in a decision which confirmed that deals made by Pfizer in relation to generic cholesterol-lowering medication do not constitute a misuse of its market power.
Editor's picks
Editor's picks
Asia-Pacific
31 May 2018 A court has rejected an appeal by the Australian Competition and Consumer Commission, in a decision which confirmed that deals made by Pfizer in relation to generic cholesterol-lowering medication do not constitute a misuse of its market power.
Asia-Pacific
31 May 2018 A court has rejected an appeal by the Australian Competition and Consumer Commission, in a decision which confirmed that deals made by Pfizer in relation to generic cholesterol-lowering medication do not constitute a misuse of its market power.